Lin BioScience, Inc. (TPEX:6696)
Taiwan · Delayed Price · Currency is TWD 386.50
+15.00 (4.04%)
Apr 2, 2026, 2:59 PM CST
Lin BioScience Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
31.97B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sunmax Biotechnology | 2.03B |
| Ever Supreme Bio Technology | 1.02B |
| EirGenix | 1.01B |
| Medigen Vaccine Biologics | 613.17M |
| TaiMed Biologics | 611.35M |
| Tanvex BioPharma | 400.97M |
| Oneness Biotech | 129.12M |
| Polaris Group | 40.60M |